NYSEARCA:CNCR

Loncar Cancer Immunotherapy ETF - CNCR Stock Forecast, Price & News

$14.16

-0.32 (-2.21%)

(As of 09/23/2022 10:10 AM ET)

Add

Today's Range: $14.06
▼
$14.16
50-Day Range: $14.16
▼
$17.98
52-Week Range: $12.76
▼
$31.41

Volume: 305 shs
Average Volume: 6,957 shs
Market Capitalization: $21.95 million

P/E Ratio: N/A
Dividend Yield: 13.09%
Price Target: N/A

Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Loncar Cancer Immunotherapy ETF and its competitors with MarketBeat's FREE daily newsletter.

30 days | 90 days | 365 days | Advanced Chart

Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Loncar Cancer Immunotherapy ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Exchange Traded Concepts

Fund NameLoncar Cancer Immunotherapy ETF

Tax ClassificationRegulated Investment Company

SymbolNYSEARCA:CNCR

Inception Date10/13/2015

Fund ManagerDenise M. Krisko

WebN/A

PhoneN/A

Fund Focus

Asset ClassEquity

BenchmarkLoncar Cancer Immunotherapy Index

CategorySector

FocusHealth Care

Development LevelDeveloped Markets

RegionNorth America

Fund Statistics

Assets Under Management$21.71 million

Average Daily Volume$3,038.60

Discount/Premium0.01%

ETF Expenses

Management Fee0.79%

Other Expenses0.00%

Total Expenses0.79%

Fee Waiver0.00%

Net Expenses0.79%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC

AdvisorExchange Traded Concepts, LLC

CustodianU.S. Bank, N.A.

DistributorQuasar Distributors, LLC

Transfer AgentU.S. Bank, N.A.

Trustee

Lead Market MakerJane Street

Geographic Exposure of CNCR

Currency Exposure of CNCR

Sector Exposure of CNCR

Industry Exposure of CNCR

CNCR Stock - Frequently Asked Questions

How have CNCR shares performed in 2022?: Loncar Cancer Immunotherapy ETF's stock was trading at $23.80 on January 1st, 2022. Since then, CNCR stock has decreased by 40.5% and is now trading at $14.16.
View the best growth stocks for 2022 here.
Is Loncar Cancer Immunotherapy ETF a good dividend stock?: Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR) pays an annual dividend of $1.85 per share and currently has a dividend yield of 13.09%. CNCR has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.

What other stocks do shareholders of Loncar Cancer Immunotherapy ETF own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Loncar Cancer Immunotherapy ETF investors own include Inovio Pharmaceuticals (INO), ARK Genomic Revolution Multi-Sector ETF (ARKG), VanEck Biotech ETF (BBH), Co-Diagnostics (CODX), Danaher (DHR), Fate Therapeutics (FATE), Gilead Sciences (GILD), GenMark Diagnostics (GNMK), iShares Genomics Immunology and Healthcare ETF (IDNA) and Novavax (NVAX).
What is Loncar Cancer Immunotherapy ETF's stock symbol?: Loncar Cancer Immunotherapy ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "CNCR."
How do I buy shares of Loncar Cancer Immunotherapy ETF?: Shares of CNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Loncar Cancer Immunotherapy ETF's stock price today?: One share of CNCR stock can currently be purchased for approximately $14.16.
How much money does Loncar Cancer Immunotherapy ETF make?: Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR) has a market capitalization of $21.95 million.

This page (NYSEARCA:CNCR) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms